<DOC>
	<DOC>NCT01755442</DOC>
	<brief_summary>This is a phase 1, randomized, double-blind, placebo-controlled, 2-way crossover study to evaluate the effect of AMG 151 on 24-hour ambulatory blood pressure and glucose levels in subjects with type 2 diabetes mellitus who are on a stable regimen of metformin alone, metformin and a dipeptidyl peptidase-4 inhibitor (DPP4), metformin and a thiazolidinedione (TZD), or metformin, a DPP4, and a TZD for a minimum of 3 months prior to randomization.</brief_summary>
	<brief_title>Investigate Effect of AMG 151 on 24-hour Ambulatory Blood Pressure &amp; Glucose Levels in Type 2 Diabetes Mellitus Subjects</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Inclusion Criteria Subjects with type 2 diabetes mellitus On a stable regimen of metformin alone, metformin and a DPP4, metformin and a TZD, or metformin, a DPP4, and a TZD for a minimum of 3 months prior to randomization Body mass indices &gt; 25 and &lt; 45 kg/m2 Hemoglobin A1c levels ≥ 7.0% and ≤ 11.0% at screening Fasting Cpeptide levels ≥ 0.2 nmol/L at screening Subject with a history of hypertension must be on a stable antihypertensive treatment (s) (type of medication, dose, and regimen) for at least 6 weeks prior to the first dose of investigational product Other criteria may apply Exclusion Criteria Subject has type 1 diabetes mellitus or history of type 1 diabetes mellitus Subject has had 2 or more emergency room visits or hospitalizations due to poor glucose control in the 6 months prior to screening Poorly controlled hypertension defined as diastolic pressure ≥ 95 mmHg or systolic ≥ 155 mmHg (confirmed by a repeat assessment) at screening Triglycerides ≥ 400 mg/dL (4.52 mmol/L) at screening Use of any known cytochrome P450 (CYP) inducers within 30 days or 5 halflives (whichever is longer), prior to receiving the first dose of investigational product. Use of any known inhibitors of CYP3A4/Pglycoprotein within the 14 days or 5 half lives (whichever is longer) prior to receiving the first dose of investigational product Other criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Ambulatory blood pressure</keyword>
	<keyword>Type 2 diabetes</keyword>
</DOC>